The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib

Abstract

Purpose Gastric metastasis of lung cancer is rare, and the cases of disappearance of gastric metastasis and liver metastasis caused by oxitinib treatment have not been reported. Methods A 47-year-old male patient with no history of diabetes, hypertension or smoking presented with chest discomfort after eating. At the time of consultation, the diagnosis of adenocarcinoma of the right lower lobe of the lung with liver and gastric metastasis was considered by pathological examination of biopsy of the fundus of the stomach near the cardia, pathological examination of CT-guided lung aspiration and pathological examination of liver occupancy aspiration, combined with immunohistochemical results. He was found to have exon 19 deletion in next generation sequencing. We performed osimertinib on him (EGFR–TKI) systemic therapy, followed by local radiation therapy to the right lower lung primary lesion. Results After systemic treatment with osimertinib and local radiotherapy of the primary site, the metastases disappeared and the primary site showed post-radiotherapy changes, and the evaluated efficacy was complete remission. Conclusions This is the first report to our knowledge of a patient who presented with gastric and hepatic metastases from lung cancer and achieved complete remission with osimertinib and local radiotherapy, with good quality of life, which also provides a basis for future clinical work and is of great significance.

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis

“…EGFR mutations represent the most common type of driver gene mutation in NSCLC, with an incidence of approximately 30–40% [ 49 , 50 ]. Numerous phase II or III clinical trials have validated the efficacy of EGFR-TKIs, demonstrating that targeted therapy considerably ameliorates the prognosis of patients with advanced NSCLC harboring EGFR mutations, compared to chemotherapy [ 38 , [51] , [52] , [53] , [54] ]. The findings also indicate that EGFR-TKIs prolong OS in the most patients, irrespective of the metastasis sites [ 38 , [51] , [52] , [53] , [54] ].…”